Vitesse Energy Announces Second Quarter 2025 Earnings Release Date and Conference Call
Those wishing to listen to the conference call may do so via phone or the Company's webcast.
Conference Call and Webcast Details:
Time: 11:00 a.m. Eastern Time
Dial-In: 877-407-0778
International Dial-In: +1 201-689-8565
Conference ID: 13755059
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=zSuC2lWE
Replay Information:
A replay of the conference call will be available through August 12, 2025, by dialing:
Dial-In: 877-660-6853
International Dial-In: +1 201-612-7415
Conference ID: 13755059
ABOUT VITESSE ENERGY, INC.
Vitesse Energy, Inc. is focused on returning capital to stockholders through owning financial interests predominantly as a non-operator in oil and gas wells drilled by leading US operators.
More information about Vitesse can be found at www.vitesse-vts.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
40 minutes ago
- Bloomberg
Life Atop China's Car Market Is Starting to Look Shaky for BYD
Life at the top is proving complex for China's leading automaker, and there are fresh challenges on the horizon. BYD Co. 's monthly sales have stagnated of late and with the summer months being a traditionally slower time for consumer purchases, that trajectory isn't expected to reverse any time soon.
Yahoo
an hour ago
- Yahoo
Lucid Soars on Multimillion Uber Deal -- Can It Go Higher Still?
Key Points Lucid claims to have the world's most advanced electric vehicles. Uber will invest $300 million into Lucid. Lucid will use tech provided by Nuro to outfit its vehicles for driverless Uber operations. 10 stocks we like better than Lucid Group › Famous investor Benjamin Graham said: "In the short run, the market is a voting machine, but in the long run, it is a weighing machine." That quote sure holds true today, after Uber Technologies (NYSE: UBER) shook up the market with its announcement that it will deploy a fleet of robotaxis as demand for autonomous driving vehicles begins to fire on all cylinders. If the market is indeed a short-term voting machine, the market has cast its vote, and Lucid Motors (NASDAQ: LCID) looks like the real winner of this partnership. Lucid's stock popped well over 40% on the news, while Uber traded marginally higher. Let's dig into what this massive development means for the young electric vehicle (EV) maker. Best of the best? When it comes to selecting partners for such a massive deal, Uber could have done a lot worse than selecting the EV company that's brash enough to claim "maker of the world's most advanced electric vehicles." More specifically, on Thursday, Uber announced a partnership that would unleash more than 20,000 robotaxis over the next six years. As previously mentioned, part of the partnership includes Lucid, but another partner is also in the mix: Nuro, an autonomous vehicle start-up. It breaks down like this: Uber will invest $300 million in Lucid, while Nuro develops the self-driving technology that Lucid will deploy in its vehicles to supply Uber with robotaxis. "This investment from Uber further validates Lucid's fully redundant zonal architecture and highly capable platform as ideal for autonomous vehicles, and our industry-leading range and spacious well-appointed interiors, as ideal for ridesharing," said Marc Winterhoff, Interim CEO at Lucid, in a press release. "This is the start of our path to extend our innovation and technology leadership into this multi-trillion-dollar market." This development is a pretty big deal for Lucid. While manufacturing of the 20,000 vehicles in question will be spread over six years and unlikely to start until late next year, it still represents a strong order for the company that just set a quarterly record for deliveries at only 3,309 vehicles, during the second quarter. Moreover, consider that Lucid delivered only 6,418 vehicles during the first half of 2025, and you can understand that 20,000 vehicles for Uber is nothing to sneeze at. In fact, it's about as many vehicles as Lucid hopes to deliver for the full year. Strategic change This partnership marks a new era for Uber, which previously exited the robotaxi space in 2020, and signals that the company's strategy going forward will revolve around partnerships with multiple technology developers. It's also not the only deal Uber is working on. In April, the company announced that Volkswagen will supply its vans for commercial service in Los Angeles next year. While Uber is the driving force behind this multi-million-dollar partnership, it arguably has the roughest road ahead. Driverless vehicle technology has been more challenging and more costly than anticipated, and it's dealing with tight regulations and federal investigations. Those hurdles caused many start-ups to close their doors, including General Motors' Cruise and Ford Motor Company's Argo AI. Uber also has some catching up to do in terms of driverless capabilities. Despite years of delays and missed targets, Tesla did start a pilot program with about a dozen Model Y EVs in Austin, Texas, in June, with plans to expand the service to other U.S. cities later this year. Waymo has also been methodically and quietly growing its operations for years in several U.S. cities with a fleet of roughly 1,500 vehicles. It just crossed 100 million miles of autonomous driving in July. Ultimately, this opens the door to new opportunities for all three companies. But if the market is indeed a voting machine in the short term, there is reason for Lucid investors to be excited. This gets the company's product in front of new customers, in a new addressable market, with partnerships that were once untapped -- it's a big deal, even aside from the $300 million investment. Lucid has a lot of momentum behind it right now, and if the Gravity SUV continues to accelerate its production and deliveries flawlessly, the young EV maker should enter 2026 poised for a tremendous year. While Lucid is likely to give back some of Thursday's large gains, there's little stopping Lucid's stock from climbing higher as deliveries ramp for the Gravity -- especially if the automaker can curb costs and cash burn in the year ahead. Should you buy stock in Lucid Group right now? Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Daniel Miller has positions in Ford Motor Company and General Motors. The Motley Fool has positions in and recommends Tesla and Uber Technologies. The Motley Fool recommends General Motors and Volkswagen Ag. The Motley Fool has a disclosure policy. Lucid Soars on Multimillion Uber Deal -- Can It Go Higher Still? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
